Health Care

Lineage Cell Therapeutics’ latest insider activity shows CEO Brian Culley and senior execs aligning long‑term incentives with shareholder value as the company pushes cell‑therapy milestones, tackles regulatory & reimbursement hurdles, and leverages …

BrightSpring insider trades reveal executive confidence: buying deep‑discount shares and selling at market prices after a $20 M offering, highlighting growth potential in specialty pharmacy and diagnostic imaging.

Amgen insider Bradway’s $156/share purchase shows confidence in biotech growth and dividend prospects, offering a rare low‑price entry for long‑term investors.

Enovis insider sales show routine portfolio moves, not a confidence shift; meanwhile, its EPDS device gains FDA clearance and promising phase‑III results, hinting at future market impact.

Explore how Ligand Inc.’s insider trades reveal a disciplined investment strategy, market valuation insights, and pipeline potential for oncology and hormone therapies.

Explore how Bicara Therapeutics’ executive Rule 10b‑5 trades align with a growing stock rally, robust pipeline milestones, and strong governance for investors.

Insightful analysis of Madrigal Pharmaceuticals’ insider buying, revealing strong confidence in its small‑molecule cardiovascular pipeline and long‑term value.

Explore how Carlyle Group’s recent Medline share purchase signals confidence and strategic buying, and what it means for investors.

Discover how Sionna Therapeutics’ insider buying and selling signals confidence yet reveals market challenges, and what this means for investors and future growth.

Insider buying by Ligand Pharmaceuticals’ chief legal officer shows confidence in a high‑growth, hormone‑targeted biotech amid market volatility and strategic shelf‑offer funding plans.